The recommended phase 2 dose (RP2D) of anticancer agents is determined traditionally by dose-limiting toxicities. Nontoxicity or biological endpoints such as pharmacokinetics, pharmacodynamics, and efficacy can also be used to identify RP2D, which may be relevant to molecularly targeted agents (MTAs). METHODS: A systematic review identified all monotherapy phase 1 studies of MTAs in solid tumors published between 2001 and 2013. Dose, dosing schedule, and determinants of RP2D were collected from each study. A supplementary search of the US Food and Drug Administration (FDA) website identified the licensed dose for drugs with regulatory approval. Logistic regression was used to explore predictors for the RP2D being consistent with the final approved dose. RESULTS: The search identified 4175 records, of which 250 studies evaluating 181 individual MTAs were included. Of these MTAs, 161 (64%) determined an RP2D. Fifty-two trials (32%), used toxicity alone to specify an RP2D. The remaining trials used a nonclassical approach with either multiple endpoints that included toxicity (n 5 87, 54%), multiple nontoxicity endpoints (n 5 12, 7%), or a single nontoxicity endpoint (n 5 10, 6%). Twenty-nine (16%) MTAs were approved by the FDA for solid tumor indications. The use of nonclassical definitions compared with toxicity alone was significantly associated with higher likelihood of FDA approval (odds ratio, 5.03; 95% confidence interval, 1.11-22.73; P 5 .036). CONCLUSIONS: In the past decade, there has been a dominance of a nonclassical approach using multiple endpoints with or without toxicity or single nontoxicity endpoints to define RPTD in MTA monotherapy phase 1 trials. Nonclassically defined RP2Ds for MTAs appear to be associated with a higher rate of FDA drug approval. Cancer 2017;123:1409-15.
INTRODUCTION
The key objective of a phase 1 trial is to identify the recommended phase 2 dose (RP2D) of an experimental therapy for the dosing schedule that is being tested. Conventionally, for cytotoxic agents, the RP2D has been determined by the frequency of dose-limiting toxicities (DLTs) under the assumption that the highest tolerable dose will result in the greatest likelihood of efficacy. 1, 2 However, in the era of molecular targeted agents (MTAs), the optimal method to define RP2D remains unclear, because clinical benefit is not necessarily dose dependent. [3] [4] [5] [6] A previous analysis of phase 1 trials of MTAs demonstrated that there was no difference in outcomes between patients assigned to low (25% maximum tolerated dose [MTD] ), medium (25%-75% MTD), or high (75% MTD) dose cohorts. 7 This dataset supports the concept that dose-response relationships between chemotherapies and MTA are different. Furthermore, DLT definitions have been shown to be heterogeneous between trials 8 and may not capture toxicities of chronic dosing, which is more common with MTA. 9, 10 This leads to some uncertainty about the application of a classical approach using toxicity alone to define RP2D for MTA. Beyond toxicity, a mechanistic evaluation of drug effects through pharmacodynamic (PD) markers such as tissue, molecular or imaging measures; or drug pharmacokinetic (PK) parameters could be used to identify the biologically effective doses. 11 Nonclassical approaches including biological or nontoxicity endpoints such as PD, PK, and efficacy could be used with or without toxicity to specify RP2D as an alternative to toxicity alone.
Approximately 5% of oncology drugs tested in a phase 1 setting receive approval from the US Food and Drug Administration (FDA). [12] [13] [14] Poor drug activity and safety issues are major reasons for failure. 15 For MTAs, it is unclear how nontoxicity or biological endpoints such as PK, PD, and efficacy can be used to define RP2D and the subsequent effect on drug approval. We reviewed the determinants of the RP2D for MTAs and explored the concordance of the RP2D with the final FDA-approved dose (ie, the label dose). We hypothesized that the RP2D for MTAs defined by biological endpoints with or without toxicity would be used more frequently in phase 1 trials than toxicity alone.
MATERIALS AND METHODS

Data Sources and Searches
A comprehensive literature search for prospective clinical trials of MTAs in solid tumors published between 2001 and 2013 was conducted in Ovid (MEDLINE, EMBASE, and Cochrane databases). The main search terms included molecular targeted therapy, neoplasm, and clinical trial (see online supporting information). Phase 1 clinical trials in adult patients with solid tumors that were published in English were included. Duplicates, abstracts, case reports, case series, correlative studies, secondary reporting of clinical trials, nonclinical studies, trials in hematological malignancy, non-phase 1 studies, trials of chemotherapy, studies conducted in patients without cancer or in children, studies not testing an anticancer therapy, combination studies such as those combining systemic therapy with radiation, stem cell or bone marrow transplantation studies, and supportive care studies were excluded. Singleagent phase 1 studies of MTAs were included. The search was conducted in July 2013. A supplementary search of the Drugs@FDA website 16 was performed for the individual drugs that were included to determine whether they had been approved by the FDA. In addition, a search for later phase 2 and 3 trials in MEDLINE was performed for each included drug. These supplementary searches were conducted in August 2015 using the drug names. The intent of this review was to capture systematically phase 1 trials of MTA and then prospectively evaluate which agents were tested in later phase trials and subsequently received FDA approval. Typically, the time between publication of the phase 1 trial and FDA approval is a number of years. To account for this lag time and to maximize the number of MTAs that could be included, the two searches were conducted 2 years apart.
Study Selection
We defined inclusion and exclusion criteria a priori. Two reviewers (A.R.H. and N.C.) evaluated the titles and abstracts of publications identified by the search strategy, and any publication thought to be potentially relevant was retrieved in full. The same 2 reviewers then assessed full publications for eligibility. Reviewers were not blinded to study authors or outcomes. The decision to include a study for review was made by consensus between the reviewers. The plan to resolve disagreements involved a third author (A.R.A.R.); however, no unresolved differences occurred.
Data Extraction
The same two reviewers extracted data from the included trials. Data extracted from clinical studies included drug type; RP2D and schedule; toxicity, efficacy, PK, and PD data; determinants of RP2D (eg, toxicity, PK, PD, or efficacy such as overall response, progression-free survival, and overall survival); study sample size; region of study; molecular selection; and tumor type. RP2D data extraction was based on it being 1) explicitly stated or 2) based on the number of DLTs observed together with information/rules on RP2D determination in individual studies. Supporting information was collected on drugs from the Drugs@FDA website 16 for an approved drug's prescribing information and label dose. In this review, the RP2D was the dose defined in the phase 1 study. The label dose was the dose listed on the FDA-approved drug label.
Study Objectives
The primary objective was to describe the determinants of an RP2D in phase 1 clinical trials of MTAs. Secondary goals included exploring the associations between the RP2D and other select study characteristics, such as year of publication, number of endpoints, and study size. Finally, predictors of concordance between the RP2D and the final approved dose were explored among the subgroup of MTAs that received regulatory approval. Concordance between the RP2D and the FDA label dose was used as a surrogate for accuracy of the RP2D and to demonstrate that the RP2D was clinically active.
Statistical Analysis
Data were presented descriptively as means, proportions, and ranges as appropriate. The RP2D could be defined by a single endpoint (toxicity or nontoxicity) or multiple endpoints, which either included or did not include toxicity. Traditionally, the RP2D has been specified by toxicity alone (ie, a classical approach). We considered the use of Original Article any other definition such as a single, nontoxicity endpoint (eg, PD, PK, or efficacy) or multiple endpoints (including those containing toxicity as part of a composite endpoint) as a nonclassical approach. If an MTA was tested in multiple trials, it was considered to have a classically defined RP2D only if all trials used toxicity alone to specify the RP2D; otherwise, it was classified as having a nonclassical RP2D. The rationale for this classification was that the FDA considers information from all trials at the time of drug approval. The RP2D was considered concordant with FDA label dose if in any trial that tested the MTA, the RP2D was the same as the label dose. MTAs that had no trial that specified an RP2D were considered not comparable with the FDA label dose. Trends of use of specific endpoints over time were explored by linear regression. Associations between baseline study characteristics, endpoints, FDA approval, and concordance between the RP2D and the FDA label dose were evaluated using logistic regression. Statistical analyses were performed using SPSS version 21 (IBM Corp, Armonk, NY). All statistical tests were 2-sided, and statistical significance was defined as P < .05. No corrections were made for multiple testing.
RESULTS
Phase I Trial Characteristics
The search identified 4175 records, of which 250 studies evaluating 181 MTAs (Supporting Information, Supplement 1) were included in the analysis (Fig. 1) . The majority of MTAs were small molecule, nontyrosine kinase inhibitors (n 5 56, 31%), followed by tyrosine kinase inhibitors TKIs (n 5 41, 23%) and then biopharmaceutical-derived products (BDP) (32 monoclonal antibodies, 18% of which included 2 checkpoint inhibitors; 10 recombinant fusion proteins, 5%; 2 antibody drug conjugates, 1%). "Immune" agents (n 5 13, 7%) included viruses, gene transfer, adoptive transfer, vaccines, and cytokines. Endocrine agents, vitamins, antisense molecules, peptides, lipids, oligosaccharides, ribozymes, diphenylheptanoids, and histone modulators were classified as "other MTAs" (n 5 27, 15%).
A total of 9220 patients were enrolled in all studies included for analysis. The median individual study sample size was 28 (range, 7-184). The characteristics of the trials are listed in Table 1 . The majority of trials enrolled mixed tumor types (72.8%) and usually involved multiple participating study sites (64%). Data on toxicity, PK, PD, and efficacy were reported in 99%, 92%, 75%, and 95% of trials, respectively.
Determination of RP2D
Of the 250 evaluable studies, 161 (64%) declared an RP2D (Supporting Information, Supplement 1). Among trials with a defined RP2D, a single endpoint was used in 62 cases (39%) and multiple endpoints were used in 99 cases (61%). Fifty-two trials (32%) used toxicity alone as an endpoint. The remaining trials used a nonclassical approach with any of the following: multiple endpoints that included toxicity (n 5 87, 54%), multiple nontoxicity endpoints (n 5 12, 7%), or a single nontoxicity endpoint (n 5 10, 6%) to specify RP2D. Supplement 2 in the Supporting Information outlines the endpoints used to define RP2D, and Table 2 summarizes endpoints according to MTA class. There was an increasing use of PD and efficacy endpoints to define RP2D over time (trend P 5 .04 and P 5 .006, respectively). However, the odds of actually defining the RP2D had a modest decline over time (odds ratio, 0.91; 95% confidence interval, 0.83-0.99; P 5 .04). Furthermore, there was no association between the mechanism of action of an MTA (signal transduction versus other) or study sample size with RP2D determination. Notably, only 17 (7%) trials used a molecular selection strategy to enroll patients. Seven trials declared an RP2D, and of these only 1 used the classical definition. Of the 6 trials that used a nonclassical definition of an RP2D, 1 used a PD endpoint in combination with other endpoints, 3 used PK in combination with other endpoints, and 1 used PK as the sole endpoint to specify RP2D.
Overview of MTA in Phase 1, 2, and 3 Trials
Of the 181 MTAs included in the analysis, 38 (21%) were tested in 2 or more phase 1 trials to evaluate different schedules and doses or to assess the agent in different patient populations. At the time of analysis, of these 181 MTAs, 60 (33%) of the agents did not progress beyond phase 1 testing. Subsequently, 121 (67%) and 44 (24%) MTAs were tested as monotherapy in phase 2 and 3 trials, respectively.
FDA Approved and Non-FDA-approved MTA
Of the 181 MTAs included in the analysis, 29 (16%) were approved by the FDA for solid tumor indications which were tested in 69 early phase trials (Supporting Figure 2 compares the endpoints used to determine the RP2D for these drugs. For both FDA-approved and non-FDA-approved agents, the RP2D was defined more frequently with nonclassical endpoints. The use of nonclassical definitions compared with toxicity alone was significantly associated with FDA approval, with an odds ratio of 5.03 (95% confidence interval, 1.11-22.73; P 5 .036). Among the 24 FDA-approved MTAs that had a nonclassical RP2D, 6 (25%) were BDPs. Only 2 FDAapproved MTAs had an RP2D specified by toxicity alone, and 1 (50%) of these was a BDP. For non-FDAapproved MTAs that had RP2D determined by single toxicity endpoint and nonclassical endpoints, 19% (5/26) and 8% (5/62) were BDPs, respectively. The distribution of BDPs between MTAs with classical and nonclassical RP2D derivation was similar for both FDA-approved (Fisher's exact test; P 5 .47) and non-FDA-approved (Fisher's exact test; P 5 .15) agents.
Concordance Between RP2D and FDAApproved Dose
Of the 26 FDA-approved MTAs in solid tumors that defined an RP2D, 21 (81%) had a concordant RP2D with the FDA label dose and 5 (19%) had discordant RP2D and FDA label doses. Figure 3 compares the endpoints used to determine RP2D for MTAs with concordant and discordant doses. The vast majority of MTAs with concordant doses used a nonclassical RP2D (19/21, 90%) . No MTA with discordant doses used toxicity alone to specify RP2D. The association between classical RP2D determination and concordance between the RP2D and the FDA-approved dose cannot be estimated, as none of the drugs with discordant doses were studied exclusively in trials with nonclassical RP2D determination.
DISCUSSION
This systematic review has demonstrated that the use of nontoxicity endpoints has increased over time and nonclassical RP2D appears to be associated with greater likelihood of FDA approval in solid tumors. To our knowledge, there are no data reporting the determinants of RP2D for MTA and the subsequent effect this can have on the drug approval process.
In a recent review of tumor biopsies in phase 1 trials by Sweis et al, 17 the use of biomarkers increased over time, and PD parameters were found to confirm expected target engagement but did not affect drug development or dose selection. Our review reported similar results with increasing use of PD endpoints over time. However, our review covered a longer period and used a more comprehensive search strategy, and our data collection encompassed toxicity, PD, PK, and efficacy endpoints. Unlike the review by Sweis et al, we report that nontoxicity endpoints may impact how an RP2D of an MTA is defined as well as its subsequent FDA approval. A previous review demonstrated that BDPs have tolerable toxicity profiles, and typically the RP2D was specified using nontoxicity endpoints. 18 In our analysis, nonclassical RP2D determination was used at similar frequencies in trials of BDPs compared with other MTAs. The proportion of BDPs was similar among trials using classical and nonclassical approaches in both FDA-approved and non-FDAapproved cohorts.
Although there is enthusiasm to use nontoxicity endpoints to define an RP2D, 19 there are several challenges to the implementation of these parameters. The classical phase 1 trial enrolls small cohorts of patients, which may not be adequate to define the PD and PK profile of an MTA. Furthermore, dose escalation decisions are based on DLT frequency and are not typically influenced by PK and PD readouts. Thus, these escalation methods are not designed specifically to use nontoxicity endpoints. 20 Incorporating PK and PD endpoints generally will involve multiple blood draws, fresh tumor biopsies, functional imaging, and development of robust diagnostic assays. 21 In addition, the optimal timing of these tests to measure biological activity is not known with precision. Often these correlative studies are not validated before the phase 1 trial, and there is a lack of rigorous testing in preclinical models to establish mechanistic correlations between PK or PD biomarkers and efficacy. Without analytically validated assays, modulation of the drug target and other drug properties cannot be assessed reliably. However, developing these assays in preclinical models and having them ready before the phase 1 trial is not often possible. These issues can influence how protocol-defined endpoints are interpreted to derive the RP2D. These reasons limit the feasibility of biological endpoints as determinants of RP2D to MTA that have well-defined PK measures or reliable PD thresholds.
Nevertheless, biological endpoints should be used in phase 1 trials to permit a comprehensive evaluation of MTAs. These alternative endpoints are worthy of further investigation and can support the definition of the RP2D. Expansion cohorts that test multiple doses and schedules-including the MTD and dose levels supported by PK and/or PD parameters-can provide a preliminary assessment of clinical activity. 22 Furthermore, a randomized evaluation of multiple RP2Ds at the end of a phase 1 trial may permit the selection of the most appropriate dose. This approach may be especially useful for trials that use nontoxicity endpoints to specify the RP2D. 23 This study has some limitations. A proportion of FDA-approved MTAs lack publicly available phase 1 data to determine reasons for RP2D determination, which precluded their inclusion in this study. In addition, this review may have been impacted by publication bias; phase 1 trials of drugs advancing to later phases of development are more likely to be published in full. Additionally, given the small sample size of this review, multivariable analyses were not possible, and estimates were subject to variability. In particular, the very small decrease over time of RP2D determination would disappear or be further diluted if more studies were eligible for inclusion. Caution is advised regarding any inference of causality based on the results of this study. The definitions used in each study to derive an RP2D were not evaluated in this review, but they have been reported to vary between trials. 8 The impact of this heterogeneity on dose escalation decisions and ultimately the RP2D is not known. Finally, this study can only show associations between endpoints and FDA approval and cannot prove causality between these endpoints and drug registration. We have demonstrated that the RP2D of an MTA is typically defined using multiple endpoints with or without toxicity or single nontoxicity endpoints. Determination of an RP2D using nontoxicity endpoints represents an appealing alternative to classical methods for MTAs. Furthermore, nonclassically defined RP2Ds for MTAs are associated with a higher rate of FDA approval, but this does not result in greater concordance between RP2D and FDA label dose. Phase 1 studies of MTAs should explore nontoxicity parameters to aid in RP2D determination and possibly support subsequent FDA approval.
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